Diabetes drug metformin takes on leukemia gene
NCT ID NCT07188740
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tests whether metformin, a common diabetes drug, can lower the level of a harmful gene mutation (DNMT3A R882) in 30 people with acute leukemia who are in remission. Participants will take metformin pills for 6 months, and researchers will check if the mutation decreases. The goal is to see if this approach can help prevent the leukemia from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metformin
What this could lead to
If it works, this could point toward a way to lower the risk of leukemia relapse by targeting a specific gene mutation.
What could go wrong
This is a very early, small phase 1 trial with only 30 participants. It may not show a clear benefit, and metformin can cause side effects like stomach upset or low blood sugar.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••